Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Immunological Reviews|February 1, 2025
Inflammasome Activation by RNA Respiratory Viruses: Mechanisms, Viral Manipulation, and Therapeutic InsightsTamara S Rodrigues, Dario S Zamboni
Current Opinion in Immunology|September 13, 2023
Inflammasome activation by SARS-CoV-2 and its participation in COVID-19 exacerbationTamara S Rodrigues, Dario S Zamboni
Nature Communications|February 24, 2023
Gasdermin-D activation promotes NLRP3 activation and host resistance to Leishmania infectionKeyla S G de Sá, Luana A Amaral, Tamara S Rodrigues, et al.
Nature Communications|January 8, 2020
Publisher Correction: Leishmania RNA virus exacerbates Leishmaniasis by subverting innate immunity via TLR3-mediated NLRP3 inflammasome inhibitionRenan V H de Carvalho, Djalma S Lima-Junior, Marcus Vinícius G da Silva, et al.
Nature Communications|November 23, 2019
Leishmania RNA virus exacerbates Leishmaniasis by subverting innate immunity via TLR3-mediated NLRP3 inflammasome inhibitionRenan V H de Carvalho, Djalma S Lima-Junior, Marcus Vinícius G da Silva, et al.
Plos Pathogens|June 5, 2024
Pulmonary inflammation and viral replication define distinct clinical outcomes in fatal cases of COVID-19Keyla S G de Sá, Luana A Amaral, Tamara S Rodrigues, et al.
The Journal of Pathology|November 28, 2022
Cell death induced by NLRP3-palmitate axis impairs pulmonary damage tolerance and aggravates immunopathology during obesity-tuberculosis comorbiditySandra P Palma Albornoz, Thais Fc Fraga-Silva, Renan Vh de Carvalho, et al.
The Journal of Infectious Diseases|February 10, 2023
CASP4/11 Contributes to NLRP3 Activation and COVID-19 ExacerbationTamara S Rodrigues, Camila C S Caetano, Keyla S G de Sá, et al.
Science Advances|September 14, 2022
Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infectionLetícia de Almeida, Alexandre L N da Silva, Tamara S Rodrigues, et al.
RMD Open|February 5, 2021
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trialMaria Isabel Lopes, Leticia P Bonjorno, Marcela C Giannini, et al.
Pageof 2